In a rat model of bone cancer pain or ischemia-reperfusion induced inflammatory pain, both SDF1 neutralizing antibody and AMD3100 could suppress the development of pain hypersensitivity through inhibiting astrocytic and microglial activation (Shen et al., 2014; Hu et al., 2015; Li et al., 2016). The gene discussed is CXCL12; the disease is bone cancer.